$BIMI
BIMI Holdings Inc. Stock $bimi

$bimi Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022050072 Filed on August 22, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$7.315M	$4.927M	$1.877M
YoY Change	-46.91%	-46.77%	-66.05%
Cost Of Revenue	$5.730M	$3.702M	$1.867M
YoY Change	-51.23%	-49.23%	-136.4%
Gross Profit	$1.585M	$1.225M	$10.18K
YoY Change	-21.9%	-37.63%	-99.9%
Gross Profit Margin	21.66%	24.87%	0.54%
Selling, General & Admin	$4.677M	$3.504M	$3.181M
YoY Change	30.84%	65.67%	-1063.93%
% of Gross Profit	295.12%	285.96%	31247.25%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$39.46K	$36.62K	$64.97K
YoY Change	-34.61%	-53.53%	-108.66%
% of Gross Profit	2.49%	2.99%	638.21%
Operating Expenses	$4.677M	$3.504M	$3.181M
YoY Change	30.84%	65.67%	-1063.93%
Operating Profit	-$3.092M	-$2.279M	-$3.171M
YoY Change	100.09%	1414.78%	-128.85%
Interest Expense	$97.37K	$111.6K	-$100.5K
YoY Change	-215.49%	18.83%	-108.51%
% of Operating Profit
Other Income/Expense, Net	-$622.7K	-$1.859M	-$264.7K
YoY Change	738.06%	1559.44%	-96.21%
Pretax Income	-$3.715M	-$4.138M	-$29.66M
YoY Change	118.01%	1476.53%	623.51%
Income Tax	-$575.00	$8.210K	-$18.57K
% Of Pretax Income
Net Earnings	-$3.713M	-$4.145M	-$29.67M
YoY Change	117.96%	1401.87%	1072.86%
Net Earnings / Revenue	-50.76%	-84.12%	-1580.63%
Basic Earnings Per Share	-$0.16	-$0.18
Diluted Earnings Per Share	-$0.16	-$0.18	-$27.67M
COMMON SHARES
Basic Shares Outstanding	22.86M shares	22.86M shares
Diluted Shares Outstanding	23.19M shares	22.86M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.047M	$5.034M	$4.798M
YoY Change	398.99%	703.5%	3327.04%
Cash & Equivalents	$1.047M	$5.034M	$4.798M
Short-Term Investments
Other Short-Term Assets	$5.669M	$7.392M	$4.749M
YoY Change	-48.32%	-25.93%	-72.82%
Inventory	$1.230M	$3.028M	$2.640M
Prepaid Expenses
Receivables	$7.093M	$5.945M	$7.005M
Other Receivables	$2.346M	$2.779M	$1.968M
Total Short-Term Assets	$17.38M	$24.18M	$21.16M
YoY Change	-33.91%	-5.65%	-15.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.884M	$3.112M	$3.521M
YoY Change	-52.81%	-50.94%	286.97%
Goodwill	$8.376M	$8.376M	$8.376M
YoY Change		-7.62%	21.14%
Intangibles	$15.87K	$16.79K	$18.04K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$366.4K	$197.2K	$207.6K
YoY Change	79.44%	7.02%	9.24%
Total Long-Term Assets	$15.62M	$16.04M	$16.97M
YoY Change	-57.53%	-56.63%	111.58%
TOTAL ASSETS
Total Short-Term Assets	$17.38M	$24.18M	$21.16M
Total Long-Term Assets	$15.62M	$16.04M	$16.97M
Total Assets	$33.00M	$40.22M	$38.13M
YoY Change	-47.68%	-35.77%	14.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.232M	$5.850M	$7.339M
YoY Change	-68.58%	-46.13%	25.46%
Accrued Expenses	$3.176M	$3.085M	$3.083M
YoY Change	96.39%	101.62%	250.36%
Deferred Revenue
YoY Change
Short-Term Debt	$1.383M	$1.657M	$1.799M
YoY Change	-76.86%	-75.72%	-57.46%
Long-Term Debt Due	$183.2K	$369.2K	$369.2K
YoY Change			1130.63%
Total Short-Term Liabilities	$18.90M	$21.51M	$22.09M
YoY Change	-21.86%	-22.23%	41.89%
LONG-TERM LIABILITIES
Long-Term Debt	$475.0K	$471.5K	$538.0K
YoY Change	-40.21%	-48.97%	-25.28%
Other Long-Term Liabilities	$3.419M	$3.840M	$4.162M
YoY Change	3.32%	13.18%	20708.95%
Total Long-Term Liabilities	$3.894M	$4.312M	$4.700M
YoY Change	-5.11%	-0.12%	535.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.90M	$21.51M	$22.09M
Total Long-Term Liabilities	$3.894M	$4.312M	$4.700M
Total Liabilities	$22.79M	$25.82M	$26.79M
YoY Change	-20.16%	-19.87%	62.47%
SHAREHOLDERS EQUITY
Retained Earnings			-$47.90M
YoY Change
Common Stock	$65.80M	$65.86M	$55.23M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.798M	$14.16M	$11.19M
YoY Change
Total Liabilities & Shareholders Equity	$33.00M	$40.22M	$38.13M
YoY Change	-47.68%	-35.77%	14.84%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.713M	-$4.145M	-$29.67M
YoY Change	117.96%	1401.87%	1072.86%
Depreciation, Depletion And Amortization	$39.46K	$36.62K	$64.97K
YoY Change	-34.61%	-53.53%	-108.66%
Cash From Operating Activities	-$8.285M	$3.106M	$1.272M
YoY Change	-895.47%	-267.02%	-281.74%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$989.9K
YoY Change	-100.0%	-100.0%	-807.04%
Acquisitions
YoY Change
Other Investing Activities	-$180.0K	$0.00	$118.2K
YoY Change	105.64%	-100.0%	-101.08%
Cash From Investing Activities	-$180.0K	$0.00	$1.108M
YoY Change	-88.13%	-100.0%	-110.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.690M	247.2K	1.626M
YoY Change	1708.6%	-283.99%	261.24%
NET CHANGE
Cash From Operating Activities	-8.285M	3.106M	1.272M
Cash From Investing Activities	-180.0K	0.000	1.108M
Cash From Financing Activities	4.690M	247.2K	1.626M
Net Change In Cash	-3.776M	3.353M	4.006M
YoY Change	1647.67%	-244.43%	-135.39%
FREE CASH FLOW
Cash From Operating Activities	-$8.285M	$3.106M	$1.272M
Capital Expenditures	$0.00	$0.00	$989.9K
Free Cash Flow	-$8.285M	$3.106M	$282.3K
YoY Change	-435.31%	-303.76%	-150.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50155
	dei	Entity Registrant Name EntityRegistrantName	BIMI International Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4171832	shares
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0563302
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9th Floor, Building 2
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Chongqing Corporation Avenue
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Yuzhong District
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chongqing
	dei	Entity Address Country EntityAddressCountry	CN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	400010
	dei	City Area Code CityAreaCode	(+86)
	dei	Local Phone Number LocalPhoneNumber	023-6310 7239
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	BIMI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22859264	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5034331	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4797849	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5944616	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7005442	usd
CY2022Q2	bimi	Advances To Suppliers AdvancesToSuppliers	6453083	usd
CY2021Q4	bimi	Advances To Suppliers AdvancesToSuppliers	3163836	usd
CY2022Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	327566	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	622554	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	3027785	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2639883	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3390100	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2930083	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	24177481	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21159647	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	197167	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	207549	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3112446	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3521401	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16793	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18039	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4336481	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4845509	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8376217	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8376217	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	16039104	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16968715	usd
CY2022Q2	us-gaap	Assets Assets	40216585	usd
CY2021Q4	us-gaap	Assets Assets	38128362	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1656643	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1799394	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	179351	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	369187	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	6320075	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5211160	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5849581	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7339210	usd
CY2022Q2	bimi	Advances From Customers AdvancesFromCustomers	2322963	usd
CY2021Q4	bimi	Advances From Customers AdvancesFromCustomers	1943028	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	503037	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	730285	usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	523742	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	662777	usd
CY2022Q2	bimi	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3266413	usd
CY2021Q4	bimi	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3082917	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	887630	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	954182	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21509435	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22092140	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3840091	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4161789	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	471519	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	538006	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4311610	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4699795	usd
CY2022Q2	us-gaap	Liabilities Liabilities	25821045	usd
CY2021Q4	us-gaap	Liabilities Liabilities	26791935	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22859264	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22859264	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8502222	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8502222	shares
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65833695	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55220130	usd
CY2022Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	2263857	usd
CY2021Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	2263857	usd
CY2022Q2	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	-54596942	usd
CY2021Q4	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	-47900929	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	633967	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1601870	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11193430	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	238104	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	142997	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14395540	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11336427	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40216585	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38128362	usd
CY2022Q2	us-gaap	Revenues Revenues	4927361	usd
CY2021Q2	us-gaap	Revenues Revenues	9256987	usd
	us-gaap	Revenues Revenues	9947109	usd
	us-gaap	Revenues Revenues	11424991	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	3701901	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	7292152	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7263179	usd
	us-gaap	Cost Of Revenue CostOfRevenue	8867894	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1225460	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	1964835	usd
	us-gaap	Gross Profit GrossProfit	2683930	usd
	us-gaap	Gross Profit GrossProfit	2557097	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	704528	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	774378	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1459408	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1227014	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2799827	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1340901	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6060116	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4720915	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	3504355	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2115279	usd
	us-gaap	Operating Expenses OperatingExpenses	7519524	usd
	us-gaap	Operating Expenses OperatingExpenses	5947929	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2278895	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-150444	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4835594	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3390832	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	207	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	353	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	111560	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	93882	usd
	us-gaap	Interest Expense InterestExpense	219319	usd
	us-gaap	Interest Expense InterestExpense	138237	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2865	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-401	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1750751	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18158	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1801072	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5293	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1859239	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-112040	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2020439	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-143530	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4138134	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-262484	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6856033	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3534362	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8210	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13255	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30791	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32003	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4146344	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-275739	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6886824	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3566365	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4146344	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-275739	usd
	us-gaap	Profit Loss ProfitLoss	-6886824	usd
	us-gaap	Profit Loss ProfitLoss	-3566365	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1416	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	246	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2498	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	42861	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4144928	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-275985	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6884326	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3609226	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-417823	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-149597	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-967903	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1112	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4564167	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-425336	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7854727	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3565253	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-510069	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-10886	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-535043	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	56	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4054098	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-414450	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7319684	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3565309	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22859264	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4741407	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12525879	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6886824	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3566365	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	125781	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	118802	usd
	us-gaap	Inventory Write Down InventoryWriteDown	23620	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-572	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4739	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	585000	usd
	us-gaap	Environmental Remediation Expense EnvironmentalRemediationExpense	130419	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1108915	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1607105	usd
	bimi	Increase Decreases In Accounts Receivable IncreaseDecreasesInAccountsReceivable	-1061398	usd
	bimi	Increase Decreases In Accounts Receivable IncreaseDecreasesInAccountsReceivable	2453148	usd
	bimi	Increase Decrease In Advances To Supplier IncreaseDecreaseInAdvancesToSupplier	-7338675	usd
	bimi	Increase Decrease In Advances To Supplier IncreaseDecreaseInAdvancesToSupplier	1786217	usd
	bimi	Increase Decrease In Prepaid Deferred Expenses And Other Assets IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets	460017	usd
	bimi	Increase Decrease In Prepaid Deferred Expenses And Other Assets IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets	35075	usd
	bimi	Increase Decrease In Inventories Assets IncreaseDecreaseInInventoriesAssets	387902	usd
	bimi	Increase Decrease In Inventories Assets IncreaseDecreaseInInventoriesAssets	3972555	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-509028	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-145153	usd
	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	-1489629	usd
	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	3123104	usd
	bimi	Intangible Assets Recognized From The Equity Acquisition Of Boqi Zhengji Group IntangibleAssetsRecognizedFromTheEquityAcquisitionOfBoqiZhengjiGroup	379935	usd
	bimi	Intangible Assets Recognized From The Equity Acquisition Of Boqi Zhengji Group IntangibleAssetsRecognizedFromTheEquityAcquisitionOfBoqiZhengjiGroup	3180564	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-388250	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-158463	usd
	bimi	Increase Decreases In Accrued Taxes Payable IncreaseDecreasesInAccruedTaxesPayable	-139035	usd
	bimi	Increase Decreases In Accrued Taxes Payable IncreaseDecreasesInAccruedTaxesPayable	-389759	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	183496	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-146374	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	954999	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3589450	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	12341	usd
	bimi	Deposit For The Acquisition Of Cogmer DepositForTheAcquisitionOfCogmer	-75192	usd
	bimi	Purchase Of Property Plant Equipments PurchaseOfPropertyPlantEquipments	375235	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-287702	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	553490	usd
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	256323	usd
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	350416	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4065000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	142751	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	177253	usd
	bimi	Amount Financed From Related Parties AmountFinancedFromRelatedParties	67740	usd
	bimi	Amount Financed From Related Parties AmountFinancedFromRelatedParties	164841	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-331334	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4255662	usd
	bimi	Effect Of Exchanges Rate On Cash EffectOfExchangesRateOnCash	-387183	usd
	bimi	Effect Of Exchanges Rate On Cash EffectOfExchangesRateOnCash	117396	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	236482	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	495906	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4797849	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135308	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5034331	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	631214	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	133009	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	32003	usd
	us-gaap	Interest Paid Net InterestPaidNet	122539	usd
	us-gaap	Interest Paid Net InterestPaidNet	138237	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2000	usd
	bimi	Issuance Of Common Share For Equity IssuanceOfCommonShareForEquity	2000	usd
	bimi	Issuance Of Common Share For Equity Acquisition Of Minkang Hospital IssuanceOfCommonShareForEquityAcquisitionOfMinkangHospital	4000	usd
	bimi	Common Stock To Be Issued Upon Conversion Of Convertible Promissory Notes CommonStockToBeIssuedUponConversionOfConvertiblePromissoryNotes	600	usd
	bimi	Issuance Of Common Share Upon Conversion Of Convertible Notes IssuanceOfCommonShareUponConversionOfConvertibleNotes	104	usd
	bimi	Issuance Of Shares Of Common Stock For Payment Of Improvements To Offices IssuanceOfSharesOfCommonStockForPaymentOfImprovementsToOffices	696896	usd
	bimi	Issuance Of Common Shares Upon Cashless Exercises Of Warrants IssuanceOfCommonSharesUponCashlessExercisesOfWarrants	163	usd
	bimi	Intangible Assets Recognized From Equity Acquisition Of Pharmacy Group IntangibleAssetsRecognizedFromEquityAcquisitionOfPharmacyGroup	10443494	usd
	bimi	Goodwill Recognized From Equity Acquisition Of Guanzan Group GoodwillRecognizedFromEquityAcquisitionOfGuanzanGroup	7154392	usd
	bimi	Goodwill Recognized From Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospital GoodwillRecognizedFromEquityAcquisitionOfMinkangQiangshengAndEurasiaHospital	25354174	usd
	bimi	Outstanding Payment For Equity Acquisition Of Guanzan Group OutstandingPaymentForEquityAcquisitionOfGuanzanGroup	3065181	usd
	bimi	Outstanding Payment For Equity Acquisition OutstandingPaymentForEquityAcquisition	6100723	usd
	bimi	Outstanding Payment For Equity Acquisition Of Zhuoda OutstandingPaymentForEquityAcquisitionOfZhuoda	6100723	usd
	bimi	Outstanding Payment For Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospitals OutstandingPaymentForEquityAcquisitionOfMinkangQiangshengAndEurasiaHospitals	13023556	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. ORGANIZATION AND BUSINESS BACKGROUND</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIMI International Medical, Inc. (the “Company” or “BIMI”) was incorporated in the State of Delaware as Galli Process, Inc. on October 31, 2000. On February 7, 2002, the Company changed its name to Global Broadcast Group, Inc. On November 12, 2004, the Company changed its name to Diagnostic Corporation of America. On March 15, 2007, the Company changed its name to NF Energy Saving Corporation of America, and on August 24, 2009, the Company changed its name to NF Energy Saving Corporation. On December 16, 2019, the Company changed its name to BOQI International Medical Inc., to reflect the Company’s refocus of its business from the energy saving industry to the health care industry. Since March 7, 2012, the common stock of the Company (the “Common Stock”) has been traded on the Nasdaq Capital Market.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until October 14, 2019, the Company, through NF Energy Saving Investment Limited and its subsidiaries (the “NF Group”), operated in the energy saving enhancement technology industry in the People’s Republic of China (the “PRC”). The NF Group focused on providing services relating to energy saving technology, optimization design, energy saving reconstruction of pipeline networks and contractual energy management for the electric power, petrochemical, coal, metallurgy, construction, and municipal infrastructure development industries in the PRC and the manufacture and sales of energy-saving flow control equipment. In late 2019, the Company committed to a plan to dispose of all its equity interests in the NF Group and on March 31, 2020, the Company entered into a stock purchase agreement (the “NF SPA”) to sell the NF Group. The sale of the NF Group closed on June 23, 2020. Please refer to NOTE 7 for more information relating to the sale of the NF Group.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 14, 2019, the Company acquired 100% of the equity interests in Lasting Wisdom Holdings Limited (“Lasting”), a limited company incorporated under the laws of the British Virgin Islands (“BVI”). Lasting has limited operating activities since incorporation except for holding the ownership interest in Pukung Limited (“Pukung”), a company organized under the laws of Hong Kong. Pukung owns 100% of the equity interest in Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”), a company organized under the laws of the PRC. Xinrongxin owns all the ownership interest of Dalian Boqi Zhengji Pharmacy Chain Co., Ltd. (“Boqi Zhengji”). Boqi Zhengji operated 16 retail pharmacy stores in China at the time of the acquisition.. Xinrongxin also owns 100% equity interests in Dalian Boyi Technology Co., Ltd. (“Dalian Boyi”), a subsidiary established in January 2020 and responsible for the Company’s R&D and other technology related functions. On June 24, 2020, the Company established a wholly owned subsidiary Boyi (Liaoning) Technology Co.,Ltd (“Liaoning Boyi”), in order to be qualified to participate in local healthcare projects. On December 22, 2020, the Company established another subsidiary, Bimai Pharmaceutical (Chongqing) Co., Ltd., to replace Xinrongxin as the holding company owning all the retail, wholesale and hospital operations in China.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2020, the Company, through its wholly owned subsidiary, Xinrongxin, acquired 100% of the equity interests in Chongqing Guanzan Technology Co., Ltd. (“Guanzan”). Guanzan holds an 80% equity interest in Chongqing Shude Pharmaceutical Co., Ltd. (“Shude”, together with Guanzan, the “Guanzan Group”). Guanzan also owns 100% equity interest in Chongqing Lijiantang Pharmaceutical Co. Ltd., (‘Lijiantang”), a subsidiary established in May 2020. Lijiantang operates four retail pharmacy stores in China (collectively, the “Lijiantang Pharmacy Group”). The Lijiantang Pharmacy Group engages in the retail sale of medicine and other healthcare products to customers through its directly-owned stores. The Lijiantang Pharmacy Group offers a wide range of products, including prescription and over-the-counter (“OTC”) drugs, nutritional supplements, traditional Chinese medicines, personal and family care products and medical devices, as well as miscellaneous items.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2020, the Company entered into a stock purchase agreement to sell Boqi Zhengji. The sale of the Boqi Zhengji was closed by the end of 2020, although the government record was not updated until February 2, 2021 due to the Chinese government’s alternative working schedule and other delays caused by COVID-19.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2020, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Guoyitang Hospital (“Guoyitang”), the owner and operator of a private general hospital in Chongqing City, a city in Southwest China. The transaction closed on February 2, 2021. On December 15, 2020, the Company entered into a stock purchase agreement to acquire Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”), a private hospital in the Southeast region of China. The transaction closed on February 5, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 9, 2021, the Company entered into a stock purchase agreement to acquire three private hospitals in the PRC, Wuzhou Qiangsheng Hospital (“Qiangsheng”), Suzhou Eurasia Hospital(“Eurasia”) and Yunnan Yuxi MinKang hospital (“Minkang”). The transaction closed on May 6, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 21, 2021, Bimai Hospital Management (Chongqing) Co. Ltd. was incorporated in the PRC by the Company to manage the operations of the Company’s medical services segment (“Bimi”). Bimi together with Guoyitang, Zhongshan, Qiangsheng , Eurasia and Minkang comprise the Company’s medical services group, which operate hospitals.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 21, 2021, Pusheng Pharmaceutical Co., Ltd. was incorporated in the PRC by the Company to manage its wholesale distribution of generic drugs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 10, 2021, the Company entered into a stock purchase agreement to acquire 100% of the equity interests in Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). The transaction closed on October 8, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s wholesale segments are engaged in the distribution of medical devices and pharmaceuticals.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 20, 2021, the Company entered into a stock purchase agreement to acquire Bengbu Mali OB-GYN Hospital Co., Ltd. (“Mali Hospital”). The closing of the Mali Hospital SPA is expected to take place in September 2022, subject to necessary regulatory approvals.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 9, 2022, the Company entered into a stock purchase agreement the Chairman of the Board of the Company, Mr. Fnu Oudom, whereby Mr. Oudom agreed to purchase 12,500,000 shares of Common Stock for $5 million, or $0.40 per share (the “Chairman’s Shares”), subject to the approval of the stockholders of the Company. The purchase price per share reflects a 9% discount to the five-day average closing price of the Common Stock on NASDAQ before signing the SPA (the closing price of the Common Stock on Nasdaq on such date was $0.52). On June 9, 2022, Mr. Oudom provided the Company with $5 million as interim financing in consideration for the issuance of a $5 million subordinated promissory note (the “Chairman’s Note”), bearing no interest, which will become due and payable immediately if the sale of the Chairman’s Shares is not approved by the Company’s stockholders. The Company expects to seek stockholder approval of the sale at the upcoming annual meeting of stockholders. If approved and the Chairman’s Shares are issued, all obligations under the Chairman’s Note will have been performed and discharged in full without any payment of interest. The Company has no obligation to file a registration statement with the SEC for the resale of the Chairman’s Shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">As of June 30,2022, the details of the Company’s major subsidiaries are as follows:</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place of incorporation and <br/> kind of legal entity</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activities and <br/> place of operation</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective interest held</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lasting Wisdom Holdings Limited (“Lasting”)</span></td> <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">British Virgin Island, a limited liability company</span></td> <td style="vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pukung Limited (“Pukung”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boyi (Liaoning) Technology Co., Ltd (“Liaoning Boyi”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT Technology service research and development</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalian Boyi Technology Co., Ltd (“Dalian Boyi”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT Technology service research and development </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Guanzan Technology Co., Ltd. (“Guanzan”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of medical devices in the PRC</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Shude Pharmaceutical Co., Ltd.(“Shude”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Lijiantang Pharmaceutical Co., Ltd.(“Lijiantang”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bimai Pharmaceutical (Chongqing) Co., Ltd. </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Guoyitang Hospital Co., Ltd. </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Huzhongtang Healthy Technology Co., Ltd. </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chaohu Zhongshan Minimally Invasive Hospital Co.,Ltd. </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yunnan Yuxi Minkang Hospital Co., Ltd. </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wuzhou Qiangsheng Hospital Co., Ltd. </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suzhou Eurasia Hospital Co., Ltd.</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bimai Hospital Management (Chongqing) Co. Ltd </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital management in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pusheng Pharmaceutical Co., Ltd </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Zhuoda Pharmaceutical Co., Ltd(“Zhuoda”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Qianmei Medical Devices Co., Ltd (“Qianmei”)</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of medical devices in the PRC</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table>
CY2019Q4	bimi	Transfer Of Ownership Description TransferOfOwnershipDescription	, 2019, the Company acquired 100% of the equity interests in Lasting Wisdom Holdings Limited (“Lasting”), a limited company incorporated under the laws of the British Virgin Islands (“BVI”). Lasting has limited operating activities since incorporation except for holding the ownership interest in Pukung Limited (“Pukung”), a company organized under the laws of Hong Kong. Pukung owns 100% of the equity interest in Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”), a company organized under the laws of the PRC. Xinrongxin owns all the ownership interest of Dalian Boqi Zhengji Pharmacy Chain Co., Ltd. (“Boqi Zhengji”). Boqi Zhengji operated 16 retail pharmacy stores in China at the time of the acquisition.. Xinrongxin also owns 100% equity interests in Dalian Boyi Technology Co., Ltd. (“Dalian Boyi”), a subsidiary established in January 2020 and responsible for the Company’s R&D and other technology related functions. On June 24, 2020, the Company established a wholly owned subsidiary Boyi (Liaoning) Technology Co.,Ltd (“Liaoning Boyi”), in order to be qualified to participate in local healthcare projects. On December 22, 2020, the Company established another subsidiary, Bimai Pharmaceutical (Chongqing) Co., Ltd., to replace Xinrongxin as the holding company owning all the retail, wholesale and hospital operations in China.On March 18, 2020, the Company, through its wholly owned subsidiary, Xinrongxin, acquired 100% of the equity interests in Chongqing Guanzan Technology Co., Ltd. (“Guanzan”). Guanzan holds an 80% equity interest in Chongqing Shude Pharmaceutical Co., Ltd. (“Shude”, together with Guanzan, the “Guanzan Group”). Guanzan also owns 100% equity interest in Chongqing Lijiantang Pharmaceutical Co. Ltd., (‘Lijiantang”), a subsidiary established in May 2020. Lijiantang operates four retail pharmacy stores in China (collectively, the “Lijiantang Pharmacy Group”). The Lijiantang Pharmacy Group engages in the retail sale of medicine and other healthcare products to customers through its directly-owned stores. The Lijiantang Pharmacy Group offers a wide range of products, including prescription and over-the-counter (“OTC”) drugs, nutritional supplements, traditional Chinese medicines, personal and family care products and medical devices, as well as miscellaneous items. On December 11, 2020, the Company entered into a stock purchase agreement to sell Boqi Zhengji. The sale of the Boqi Zhengji was closed by the end of 2020, although the government record was not updated until February 2, 2021 due to the Chinese government’s alternative working schedule and other delays caused by COVID-19. On December 9, 2020, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Guoyitang Hospital (“Guoyitang”), the owner and operator of a private general hospital in Chongqing City, a city in Southwest China. The transaction closed on February 2, 2021. On December 15, 2020, the Company entered into a stock purchase agreement to acquire Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”), a private hospital in the Southeast region of China. The transaction closed on February 5, 2021. On April 9, 2021, the Company entered into a stock purchase agreement to acquire three private hospitals in the PRC, Wuzhou Qiangsheng Hospital (“Qiangsheng”), Suzhou Eurasia Hospital(“Eurasia”) and Yunnan Yuxi MinKang hospital (“Minkang”). The transaction closed on May 6, 2021. On April 21, 2021, Bimai Hospital Management (Chongqing) Co. Ltd. was incorporated in the PRC by the Company to manage the operations of the Company’s medical services segment (“Bimi”). Bimi together with Guoyitang, Zhongshan, Qiangsheng , Eurasia and Minkang comprise the Company’s medical services group, which operate hospitals. On April 21, 2021, Pusheng Pharmaceutical Co., Ltd. was incorporated in the PRC by the Company to manage its wholesale distribution of generic drugs. On September 10, 2021, the Company entered into a stock purchase agreement to acquire 100% of the equity interests in Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). The transaction closed on October 8, 2021. The Company’s wholesale segments are engaged in the distribution of medical devices and pharmaceuticals. On December 20, 2021, the Company entered into a stock purchase agreement to acquire Bengbu Mali OB-GYN Hospital Co., Ltd. (“Mali Hospital”). The closing of the Mali Hospital SPA is expected to take place in September 2022, subject to necessary regulatory approvals. On June 9, 2022, the Company entered into a stock purchase agreement the Chairman of the Board of the Company, Mr. Fnu Oudom, whereby Mr. Oudom agreed to purchase 12,500,000 shares of Common Stock for $5 million, or $0.40 per share (the “Chairman’s Shares”), subject to the approval of the stockholders of the Company. The purchase price per share reflects a 9% discount to the five-day average closing price of the Common Stock on NASDAQ before signing the SPA (the closing price of the Common Stock on Nasdaq on such date was $0.52). On June 9, 2022, Mr. Oudom provided the Company with $5 million as interim financing in consideration for the issuance of a $5 million subordinated promissory note (the “Chairman’s Note”), bearing no interest, which will become due and payable immediately if the sale of the Chairman’s Shares is not approved by the Company’s stockholders. The Company expects to seek stockholder approval of the sale at the upcoming annual meeting of stockholders. If approved and the Chairman’s Shares are issued, all obligations under the Chairman’s Note will have been performed and discharged in full without any payment of interest. The Company has no obligation to file a registration statement with the SEC for the resale of the Chairman’s Shares. As of June 30,2022, the details of the Company’s major subsidiaries are as follows: Name Place of incorporation and kind of legal entity Principal activities and place of operation Effective interest held Lasting Wisdom Holdings Limited (“Lasting”) British Virgin Island, a limited liability company Investment holding 100 % Pukung Limited (“Pukung”) Hong Kong, a limited liability company Investment holding 100 % Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”) The PRC, a limited liability company Investment holding 100 % Boyi (Liaoning) Technology Co., Ltd (“Liaoning Boyi”) The PRC, a limited liability company IT Technology service research and development 100 % Dalian Boyi Technology Co., Ltd (“Dalian Boyi”) The PRC, a limited liability company IT Technology service research and development 100 % Chongqing Guanzan Technology Co., Ltd. (“Guanzan”) The PRC, a limited liability company Wholesale distribution of medical devices in the PRC 100 % Chongqing Shude Pharmaceutical Co., Ltd.(“Shude”) The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 95 % Chongqing Lijiantang Pharmaceutical Co., Ltd.(“Lijiantang”) The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Bimai Pharmaceutical (Chongqing) Co., Ltd. The PRC, a limited liability company Investment holding 100 % Chongqing Guoyitang Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Chongqing Huzhongtang Healthy Technology Co., Ltd. The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Chaohu Zhongshan Minimally Invasive Hospital Co.,Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Yunnan Yuxi Minkang Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Wuzhou Qiangsheng Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Suzhou Eurasia Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Bimai Hospital Management (Chongqing) Co. Ltd The PRC, a limited liability company Hospital management in the PRC 100 % Pusheng Pharmaceutical Co., Ltd The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Chongqing Zhuoda Pharmaceutical Co., Ltd(“Zhuoda”) The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Chongqing Qianmei Medical Devices Co., Ltd (“Qianmei”) The PRC, a limited liability company Wholesale distribution of medical devices in the PRC 100 %
CY2020Q1	bimi	Transfer Of Ownership Description TransferOfOwnershipDescription	On March 18, 2020, the Company, through its wholly owned subsidiary, Xinrongxin, acquired 100% of the equity interests in Chongqing Guanzan Technology Co., Ltd. (“Guanzan”). Guanzan holds an 80% equity interest in Chongqing Shude Pharmaceutical Co., Ltd. (“Shude”, together with Guanzan, the “Guanzan Group”). Guanzan also owns 100% equity interest in Chongqing Lijiantang Pharmaceutical Co. Ltd., (‘Lijiantang”), a subsidiary established in May 2020. Lijiantang operates four retail pharmacy stores in China (collectively, the “Lijiantang Pharmacy Group”). The Lijiantang Pharmacy Group engages in the retail sale of medicine and other healthcare products to customers through its directly-owned stores. The Lijiantang Pharmacy Group offers a wide range of products, including prescription and over-the-counter (“OTC”) drugs, nutritional supplements, traditional Chinese medicines, personal and family care products and medical devices, as well as miscellaneous items. On December 11, 2020, the Company entered into a stock purchase agreement to sell Boqi Zhengji. The sale of the Boqi Zhengji was closed by the end of 2020, although the government record was not updated until February 2, 2021 due to the Chinese government’s alternative working schedule and other delays caused by COVID-19. On December 9, 2020, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Guoyitang Hospital (“Guoyitang”), the owner and operator of a private general hospital in Chongqing City, a city in Southwest China. The transaction closed on February 2, 2021. On December 15, 2020, the Company entered into a stock purchase agreement to acquire Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”), a private hospital in the Southeast region of China. The transaction closed on February 5, 2021. On April 9, 2021, the Company entered into a stock purchase agreement to acquire three private hospitals in the PRC, Wuzhou Qiangsheng Hospital (“Qiangsheng”), Suzhou Eurasia Hospital(“Eurasia”) and Yunnan Yuxi MinKang hospital (“Minkang”). The transaction closed on May 6, 2021. On April 21, 2021, Bimai Hospital Management (Chongqing) Co. Ltd. was incorporated in the PRC by the Company to manage the operations of the Company’s medical services segment (“Bimi”). Bimi together with Guoyitang, Zhongshan, Qiangsheng , Eurasia and Minkang comprise the Company’s medical services group, which operate hospitals. On April 21, 2021, Pusheng Pharmaceutical Co., Ltd. was incorporated in the PRC by the Company to manage its wholesale distribution of generic drugs. On September 10, 2021, the Company entered into a stock purchase agreement to acquire 100% of the equity interests in Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). The transaction closed on October 8, 2021. The Company’s wholesale segments are engaged in the distribution of medical devices and pharmaceuticals. On December 20, 2021, the Company entered into a stock purchase agreement to acquire Bengbu Mali OB-GYN Hospital Co., Ltd. (“Mali Hospital”). The closing of the Mali Hospital SPA is expected to take place in September 2022, subject to necessary regulatory approvals. On June 9, 2022, the Company entered into a stock purchase agreement the Chairman of the Board of the Company, Mr. Fnu Oudom, whereby Mr. Oudom agreed to purchase 12,500,000 shares of Common Stock for $5 million, or $0.40 per share (the “Chairman’s Shares”), subject to the approval of the stockholders of the Company. The purchase price per share reflects a 9% discount to the five-day average closing price of the Common Stock on NASDAQ before signing the SPA (the closing price of the Common Stock on Nasdaq on such date was $0.52). On June 9, 2022, Mr. Oudom provided the Company with $5 million as interim financing in consideration for the issuance of a $5 million subordinated promissory note (the “Chairman’s Note”), bearing no interest, which will become due and payable immediately if the sale of the Chairman’s Shares is not approved by the Company’s stockholders. The Company expects to seek stockholder approval of the sale at the upcoming annual meeting of stockholders. If approved and the Chairman’s Shares are issued, all obligations under the Chairman’s Note will have been performed and discharged in full without any payment of interest. The Company has no obligation to file a registration statement with the SEC for the resale of the Chairman’s Shares. As of June 30,2022, the details of the Company’s major subsidiaries are as follows: Name Place of incorporation and kind of legal entity Principal activities and place of operation Effective interest held Lasting Wisdom Holdings Limited (“Lasting”) British Virgin Island, a limited liability company Investment holding 100 % Pukung Limited (“Pukung”) Hong Kong, a limited liability company Investment holding 100 % Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”) The PRC, a limited liability company Investment holding 100 % Boyi (Liaoning) Technology Co., Ltd (“Liaoning Boyi”) The PRC, a limited liability company IT Technology service research and development 100 % Dalian Boyi Technology Co., Ltd (“Dalian Boyi”) The PRC, a limited liability company IT Technology service research and development 100 % Chongqing Guanzan Technology Co., Ltd. (“Guanzan”) The PRC, a limited liability company Wholesale distribution of medical devices in the PRC 100 % Chongqing Shude Pharmaceutical Co., Ltd.(“Shude”) The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 95 % Chongqing Lijiantang Pharmaceutical Co., Ltd.(“Lijiantang”) The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Bimai Pharmaceutical (Chongqing) Co., Ltd. The PRC, a limited liability company Investment holding 100 % Chongqing Guoyitang Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Chongqing Huzhongtang Healthy Technology Co., Ltd. The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Chaohu Zhongshan Minimally Invasive Hospital Co.,Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Yunnan Yuxi Minkang Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Wuzhou Qiangsheng Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Suzhou Eurasia Hospital Co., Ltd. The PRC, a limited liability company Hospital in the PRC 100 % Bimai Hospital Management (Chongqing) Co. Ltd The PRC, a limited liability company Hospital management in the PRC 100 % Pusheng Pharmaceutical Co., Ltd The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Chongqing Zhuoda Pharmaceutical Co., Ltd(“Zhuoda”) The PRC, a limited liability company Wholesale distribution of generic drugs in the PRC 100 % Chongqing Qianmei Medical Devices Co., Ltd (“Qianmei”) The PRC, a limited liability company Wholesale distribution of medical devices in the PRC 100 %
CY2021Q3	bimi	Equity Interest Rate EquityInterestRate	1	pure
CY2022Q2	bimi	Transfer Of Ownership Description TransferOfOwnershipDescription	On June 9, 2022, the Company entered into a stock purchase agreement the Chairman of the Board of the Company, Mr. Fnu Oudom, whereby Mr. Oudom agreed to purchase 12,500,000 shares of Common Stock for $5 million, or $0.40 per share (the “Chairman’s Shares”), subject to the approval of the stockholders of the Company. The purchase price per share reflects a 9% discount to the five-day average closing price of the Common Stock on NASDAQ before signing the SPA (the closing price of the Common Stock on Nasdaq on such date was $0.52). On June 9, 2022, Mr. Oudom provided the Company with $5 million as interim financing in consideration for the issuance of a $5 million subordinated promissory note (the “Chairman’s Note”), bearing no interest, which will become due and payable immediately if the sale of the Chairman’s Shares is not approved by the Company’s stockholders.
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	905553	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	828250	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	2102982	usd
	bimi	Total Minimum Lease Payments TotalMinimumLeasePayments	5856420	usd
	bimi	Less Amounts Representing Interest LessAmountsRepresentingInterest	-1128699	usd
	us-gaap	Other Operating Income OtherOperatingIncome	6886824	usd
	us-gaap	Other Operating Income OtherOperatingIncome	3566365	usd
CY2022Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	54600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these condensed consolidated financial statements in conformity with the US GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities on the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Significant estimates and assumptions made by management include, among others, useful lives and impairment of long-lived assets, collectability of accounts receivable, advances to suppliers’ allowance for doubtful accounts, reserve of inventory, fair value of goodwill and valuation of derivative liabilities. While the Company believes that the estimates and assumptions used in the preparation of these condensed consolidated financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q4	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	103178	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26128171	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3521401	usd
	us-gaap	Depreciation Depreciation	125781	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	305478	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	322145	usd
CY2022Q2	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	98017	usd
CY2021Q2	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	31006	usd
	us-gaap	Depreciation Depreciation	50414	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2022Q2	bimi	Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement PercentageOfIncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement	0.13	pure
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
CY2022Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.7114	pure
CY2021Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.4572	pure
CY2022Q2	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.4835	pure
CY2021Q2	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.4711	pure
CY2020Q4	bimi	Business Combination Consideration Transferred BusinessCombinationConsiderationTransferred	7374000	usd
CY2022Q2	us-gaap	Other Minority Interests OtherMinorityInterests	46295	usd
	bimi	Non Controlling Equity Interest Percentage NonControllingEquityInterestPercentage	0.20	pure
	bimi	Heacquisitionoftheqiangshengeurasiaandminkanghospitals HEACQUISITIONOFTHEQIANGSHENGEURASIAANDMINKANGHOSPITALS	<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. THE ACQUISITION OF THE QIANGSHENG, EURASIA AND MINKANG HOSPITALS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2021, the Company and Chongqing Bimai entered into a stock purchase agreement to acquire Qiangsheng, Eurasia and Minkang, three private hospitals in the PRC, having a total of 170 hospital beds. Pursuant to the agreement, the Company agreed to purchase all the issued and outstanding equity interests in Qiangsheng, Eurasia and Minkang in consideration of approximately $25,023,555 (RMB162,000,000) to paid by the issuance of 800,000 shares of Common Stock, the value of which was agreed to be RMB 78 million or $12 million and the payment of RMB 84,000,000 (approximately $13,008,734) in cash. The first payment of RMB 20,000,000 (approximately $3,097,317) was made at the closing on May 6, 2021. The second and third payments of RMB 64,000,000 (approximately $9,911,416) were subject to post-closing adjustments based on the performance of Qiangsheng, Eurasia and Minkang in 2021 and 2022. The sellers had the right to receive the second and third payments in the form of the shares of Common Stock valued at $15.00 per share or in cash. As a result of the performance failure by the three hospitals for the year ended December 31, 2021, the sellers are not eligible to receive any contingent payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the identified assets acquired and liabilities assumed pursuant to the Qiangsheng, Eurasia and Minkang acquisitions as of May 6, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Items</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-indent: -9pt; padding-left: 0.25in">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,341</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,836</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Inventories</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advances and other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,620</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Property, plant and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653,104</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,168,709</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,067,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(355,980</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advances from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Tax payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(345,870</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other payables and accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(311,174</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Lease liability-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365,788</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Lease liability-non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,988,195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total net assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,736,910</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all assets acquired, and liabilities assumed is the estimated book value of the Qiangsheng, Eurasia and Minkang hospitals. Goodwill represents the excess of the fair value of purchase price over the amounts assigned to the fair value of the assets acquired and the liabilities assumed of Qiangsheng, Eurasia and Minkang Hospitals at the acquisition date.</p>
CY2022Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6250094	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	7327587	usd
	bimi	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	305478	usd
CY2021	bimi	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	322145	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5944616	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7005442	usd
CY2022Q2	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	572	usd
	us-gaap	Payments To Suppliers PaymentsToSuppliers	6453083	usd
CY2021	us-gaap	Payments To Suppliers PaymentsToSuppliers	3163836	usd
	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	6453083	usd
CY2021	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	3163836	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2743166	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2395824	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	382636	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	347237	usd
CY2022Q2	bimi	Less Impairment Allowance LessImpairmentAllowance	98017	usd
CY2021Q4	bimi	Less Impairment Allowance LessImpairmentAllowance	103178	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	3027785	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2639883	usd
	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	98017	usd
	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	103178	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7028796	usd
CY2022Q2	bimi	Rental Security Deposits RentalSecurityDeposits	59570	usd
CY2021Q4	bimi	Rental Security Deposits RentalSecurityDeposits	63021	usd
CY2022Q2	bimi	Deposit For Property Rights Trading DepositForPropertyRightsTrading	14900	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	58238	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	293933	usd
CY2022Q2	bimi	Deposit For Purchase Of Medical Devices DepositForPurchaseOfMedicalDevices	11920	usd
CY2022Q2	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	794072	usd
CY2021Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	1227778	usd
CY2022Q2	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	1917339	usd
CY2021Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	766197	usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables	558837	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	605234	usd
CY2022Q2	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	24776	usd
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	26080	usd
CY2022Q2	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	3390100	usd
CY2021Q4	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	2930083	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7442043	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3916350	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3920642	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3112446	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20420	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21495	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3627	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3456	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16793	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18039	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1182	usd
CY2022Q2	bimi	Operating Lease OperatingLease	4336481	usd
CY2021Q4	bimi	Operating Lease OperatingLease	4845509	usd
CY2022Q2	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	4336481	usd
CY2021Q4	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	4845509	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	887630	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	954182	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3840091	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4161789	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4727721	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5115971	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1041821	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	977814	usd
CY2022Q2	bimi	Operating Lease Total OperatingLeaseTotal	4727721	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8376217	usd
CY2020Q4	us-gaap	Goodwill Goodwill	6914232	usd
CY2021	bimi	Addition During The Year AdditionDuringTheYear	27590156	usd
CY2021	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	26128171	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8376217	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8376217	usd
CY2022Q2	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1656643	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1799394	usd
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	79039	usd
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	16538	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	907193	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22859264	shares
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	369187	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	538006	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	43500	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	30676	usd
CY2021Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.108	pure
CY2022Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	142792	usd
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1458	pure
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	12.95
CY2022Q2	bimi	Shares Of Common Stock SharesOfCommonStock	130000	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.23
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	5400000	usd
CY2021Q1	bimi	Shares Of Common Stock SharesOfCommonStock	152000	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.23
CY2021Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	the “November SPA”) with the same two Institutional Investors to sell them a series of senior convertible notes (the “2021 Notes”) with an original issue discount of 20% and ranking senior to all outstanding and future indebtedness of the Company in a private placement. Each Institutional Investor paid $3,250,000 in cash for a 2021 Note in the face amount of $3,900,000. The November SPA also provided for the issuance of additional 2021 Notes in an aggregate original principal amount not to exceed $3,900,000 under certain circumstances. The November SPA also contains provisions about the Market Event Price. The 2021 Notes, which were issued on November 22, 2021, mature on the eighteen-month anniversary of the issuance date, are payable by the Company in installments and are convertible at the election of the Institutional Investors at the conversion price of $3.25 (post-Split Price and subject to the Event Market Price Adjustment), which is subject to adjustment in the event of default. Each Institutional Investor also received a warrant (the “Institutional Investor 2021 Warrant”) to purchase 180,000 shares of Common Stock at an initial exercise price of $3.55 per share (subject to the Event Market Price Adjustment). The placement agent for the private placement received a warrant (the “Placement Agent 2021 Warrant”, together with the Institutional Investor 2021 Warrant, the “2021 Warrants”) to purchase up to 8% of the aggregate number of shares of Common Stock at an initial exercise price of $3.55 per share (post-Split Price and subject to the Event Market Price Adjustment), subject to increase based on the number of shares Common Stock issued pursuant to the 2021 Notes.
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y5M1D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M1D
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On February 2, 2022, we completed a five (5) for one (1) reverse stock split (the “Reverse Split”) of our issued and outstanding ordinary shares, par value $0.001 per share.
CY2022Q2	bimi	Other Unallocated Assets Dalian Boyi OtherUnallocatedAssetsDalianBoyi	4372	usd
CY2022Q2	bimi	Social Security Payable SocialSecurityPayable	982178	usd
CY2021Q4	bimi	Social Security Payable SocialSecurityPayable	947911	usd
CY2022Q2	bimi	Accrued Operating Expenses Current AccruedOperatingExpensesCurrent	-900	usd
CY2021Q4	bimi	Accrued Operating Expenses Current AccruedOperatingExpensesCurrent	175215	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1069302	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	953959	usd
CY2022Q2	bimi	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3266413	usd
CY2021Q4	bimi	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3082917	usd
CY2019Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	500000	usd
CY2021Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1000000	usd
CY2021Q4	us-gaap	Shares Issued SharesIssued	1000000	shares
CY2022Q1	pf0	Future Net Cash Flows Relating To Proved Oil And Gas Reserves Ten Percent Annual Discount For Estimated Timing Of Cash Flows FutureNetCashFlowsRelatingToProvedOilAndGasReservesTenPercentAnnualDiscountForEstimatedTimingOfCashFlows	250000	usd
CY2022Q1	bimi	Prepayment Of Common Stock PrepaymentOfCommonStock	500000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	500000	shares
CY2022Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1000000	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	1000000	shares
CY2022Q2	us-gaap	Due To Employees Current And Noncurrent DueToEmployeesCurrentAndNoncurrent	300000	usd
CY2022Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	327566	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	622554	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	503037	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	730285	usd
	us-gaap	Debt Conversion Description DebtConversionDescription	From April 6, 2020 through October 20, 2020, Power Up Lending Group Ltd., Crown Bridge Partners, LLC, Labrys Fund, LP, Morningview Financial, LLC, TFK Investments LLC, BHP Capital NY Inc., Firstfire Global Opportunities Fund, LLC and Platinum Point Capital LLC converted $1,534,250 of convertible notes plus interest into an aggregate of 331,643 shares of Common Stock.
CY2021Q1	us-gaap	Debt Conversion Description DebtConversionDescription	On February 3, 2021, a holder of a convertible note issued on December 16, 2019, converted a part of the note in the aggregate principal amount of $ 74,473 plus interest into 20,706 shares of Common Stock.
CY2022Q2	bimi	Other Unallocated Assets Liaoning Boyi OtherUnallocatedAssetsLiaoningBoyi	31811	usd
CY2022Q2	bimi	Other Unallocated Assets Chongqing Bimai OtherUnallocatedAssetsChongqingBimai	2282943	usd
CY2022Q2	bimi	Other Unallocated Assets Bimi OtherUnallocatedAssetsBIMI	1167209	usd
CY2022Q2	bimi	Total Consolidated Assets TotalConsolidatedAssets	40216585	usd
	bimi	Total Revenues From Reportable Segments TotalRevenuesFromReportableSegments	14121913	usd
	bimi	Other Revenues OtherRevenues	38663	usd
	bimi	Elimination Of Intersegments Revenues EliminationOfIntersegmentsRevenues	2735585	usd
	bimi	Total Consolidated Revenues TotalConsolidatedRevenues	11424991	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6886824	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3566365	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12525879	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4171832	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9947109	usd
	bimi	Cost Of Revenues CostOfRevenues	7263179	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	99483	usd
	bimi	Profitloss Profitloss	-6886824	usd
	bimi	Total Asset TotalAsset	40216585	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11424991	usd
	bimi	Cost Of Revenues CostOfRevenues	8867894	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	76415	usd
	bimi	Profitloss Profitloss	-3566365	usd
	bimi	Total Asset TotalAsset	62612425	usd
	bimi	Total Revenues From Reportable Segments TotalRevenuesFromReportableSegments	10653288	usd
	bimi	Elimination Of Intersegments Revenues EliminationOfIntersegmentsRevenues	-706179	usd
	bimi	Total Consolidated Revenues TotalConsolidatedRevenues	9947109	usd
	bimi	Total Loss From Reportable Segments TotalLossFromReportableSegments	-469726	usd
	bimi	Elimination Of Intersegments Profit Or Loss EliminationOfIntersegmentsProfitOrLoss	-321432	usd
	bimi	Amortization Of Discount Of Notes And Convertible Notes AmortizationOfDiscountOfNotesAndConvertibleNotes	-771124	usd
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	5324542	usd
	bimi	Total Net Loss TotalNetLoss	-6886824	usd
CY2022Q2	bimi	Total Assets From Reportable Segments TotalAssetsFromReportableSegments	51061777	usd
CY2022Q2	bimi	Elimination Of Intersegments Receivables EliminationOfIntersegmentsReceivables	-14335851	usd
CY2022Q2	bimi	Other Unallocated Assets Xinrongxin OtherUnallocatedAssetsXinrongxin	4324	usd
	bimi	Total Loss From Reportable Segments TotalLossFromReportableSegments	13445	usd
	bimi	Elimination Of Intersegments Profit Or Loss EliminationOfIntersegmentsProfitOrLoss	2325	usd
	bimi	Amortization Of Discount Of Notes And Convertible Notes AmortizationOfDiscountOfNotesAndConvertibleNotes	-1386586	usd
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	2190899	usd
	bimi	Total Net Loss TotalNetLoss	-3566365	usd
CY2021Q2	bimi	Total Assets From Reportable Segments TotalAssetsFromReportableSegments	32546382	usd
CY2021Q2	bimi	Elimination Of Intersegments Receivables EliminationOfIntersegmentsReceivables	-8999782	usd
CY2021Q2	bimi	Other Unallocated Assets Xinrongxin OtherUnallocatedAssetsXinrongxin	3102087	usd
CY2021Q2	bimi	Other Unallocated Assets Liaoning Boyi OtherUnallocatedAssetsLiaoningBoyi	185382	usd
CY2021Q2	bimi	Other Unallocated Assets Dalian Boyi OtherUnallocatedAssetsDalianBoyi	20173	usd
CY2021Q2	bimi	Other Unallocated Assets Chongqing Bimai OtherUnallocatedAssetsChongqingBimai	2932238	usd
CY2021Q2	bimi	Other Unallocated Assets Bimi OtherUnallocatedAssetsBIMI	32825945	usd
CY2021Q2	bimi	Total Consolidated Assets TotalConsolidatedAssets	62612425	usd
	bimi	Schedule Of Revenues From Each Types Of Products Table Txet Block ScheduleOfRevenuesFromEachTypesOfProductsTableTxetBlock	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the six months ended<br/> June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical devices wholesale</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,828,557</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">916,193</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,950,198</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,732,974</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical wholesale</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,663,350</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,495,931</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmacy retail</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">505,004</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">241,230</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,947,109</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,386,328</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	bimi	Total Revenue TotalRevenue	9947109	usd
	bimi	Total Revenue TotalRevenue	11386328	usd
CY2022Q3	bimi	Annual Rent Increase Percentage AnnualRentIncreasePercentage	0.025	pure
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14157436	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12525879	shares
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Environmental Remediation Expense EnvironmentalRemediationExpense		usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
	bimi	Deposit For The Acquisition Of Cogmer DepositForTheAcquisitionOfCogmer		usd
	bimi	Purchase Of Property Plant Equipments PurchaseOfPropertyPlantEquipments		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	bimi	Issuance Of Common Share For Equity IssuanceOfCommonShareForEquity		usd
	bimi	Common Stock To Be Issued Upon Conversion Of Convertible Promissory Notes CommonStockToBeIssuedUponConversionOfConvertiblePromissoryNotes		usd
	bimi	Issuance Of Shares Of Common Stock For Payment Of Improvements To Offices IssuanceOfSharesOfCommonStockForPaymentOfImprovementsToOffices		usd
	bimi	Issuance Of Common Shares Upon Cashless Exercises Of Warrants IssuanceOfCommonSharesUponCashlessExercisesOfWarrants		usd
	bimi	Intangible Assets Recognized From Equity Acquisition Of Pharmacy Group IntangibleAssetsRecognizedFromEquityAcquisitionOfPharmacyGroup		usd
	bimi	Goodwill Recognized From Equity Acquisition Of Guanzan Group GoodwillRecognizedFromEquityAcquisitionOfGuanzanGroup		usd
	bimi	Goodwill Recognized From Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospital GoodwillRecognizedFromEquityAcquisitionOfMinkangQiangshengAndEurasiaHospital		usd
	bimi	Outstanding Payment For Equity Acquisition Of Guanzan Group OutstandingPaymentForEquityAcquisitionOfGuanzanGroup		usd
	bimi	Outstanding Payment For Equity Acquisition OutstandingPaymentForEquityAcquisition		usd
	bimi	Outstanding Payment For Equity Acquisition Of Zhuoda OutstandingPaymentForEquityAcquisitionOfZhuoda		usd
	bimi	Outstanding Payment For Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospitals OutstandingPaymentForEquityAcquisitionOfMinkangQiangshengAndEurasiaHospitals		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	bimi	Allowance For Doubtful Accounts Supplier AllowanceForDoubtfulAccountsSupplier		usd
CY2021	bimi	Allowance For Doubtful Accounts Supplier AllowanceForDoubtfulAccountsSupplier		usd
CY2022Q2	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet		usd
CY2021Q2	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	bimi	Addition During The Year AdditionDuringTheYear		usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax		usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12525879	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4171832	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	bimi	Other Revenues OtherRevenues		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001213660

Files In Submission

Name	View Source	Status
0001213900-22-050072-index-headers.html	Edgar Link	pending
0001213900-22-050072-index.html	Edgar Link	pending
0001213900-22-050072.txt	Edgar Link	pending
0001213900-22-050072-xbrl.zip	Edgar Link	pending
bimi-20220630.xsd	Edgar Link	pending
f10q0622ex31-1_bimiintern.htm	Edgar Link	pending
f10q0622ex31-2_bimiintern.htm	Edgar Link	pending
f10q0622ex32-1_bimiintern.htm	Edgar Link	pending
f10q0622ex32-2_bimiintern.htm	Edgar Link	pending
f10q0622_bimiintern.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
bimi-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bimi-20220630_lab.xml	Edgar Link	unprocessable
bimi-20220630_def.xml	Edgar Link	unprocessable
f10q0622_bimiintern_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bimi-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIMI
BIMI Holdings Inc. Stock $bimi

2022 Q3 Form 10-Q Financial Statement

#000121390022050072 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI BIMI Holdings Inc. Stock $bimi

2022 Q3 Form 10-Q Financial Statement

#000121390022050072 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI
BIMI Holdings Inc. Stock $bimi